Scientific Symposium

*Treatment of Multiple Myeloma - Standard of Care anno 2017*

Wednesday 15 November 2017, 1pm-6pm

Hotel Grand, Jernbanegade 18, 5000 Odense C.

Program

13.00-14.00  |  Arrival and Lunch

14.00-14.05  |  Welcome. Niels Abildgaard, Chairman, DMSG

14.05-14.45  |  *The French perspective – an update on IFM studies. Is MRD negativity the goal of treatment in 2017?*  
*Professor Jean Luc Harousseau, University of Nantes*

*Charlotte Pawlyn, Institute of Cancer Research, London*

15.25-15.45  |  Coffee

15.45-16.35  |  *The Danish and Nordic perspective. Short updates on ongoing and finalized studies:*
  
  “Carfi”, “CLAIM” and “Sutrica”, Henrik Gregersen, Aalborg (30 min)
  
  “ITd study”, Niels Abildgaard, Odense (10 min)
  
  “QoL – MM study”, Lene Kongsgaard Nielsen, Odense (10 min)

16.35-17.15  |  *Myeloma SoC in 2017: Limited duration or. Continued Treatment*
  
  **Limited duration treatment;** Jean Luc Harousseau (15 min)
  
  **Continued treatment;** Charlotte Pawlyn (15 min)
  
  **Debate** (10 min)

17.15-17.30  |  Break

17.30-18.00  |  *DMSG Young Investigator Award 2016: MD, PhD Jakub Krejci*
  
  - Introduction and Award: Niels Abildgaard
  
  - Lecture by Jakub Krejci: *“Mechanisms of Daratumumab action in multiple myeloma”*

18.00  |  Adjourn

*The symposium is sponsored by pharmaceutical companies and*